Immunology and gene therapy CEO and scientist presents innovative vector modifications at industry summit
The Next Generation Gene Therapy Vectors Summit is an annual event dedicated to overcoming the current immunogenicity, toxicity and manufacturability challenges facing the field by pioneering the next generation of superior delivery vectors.
Industry pioneers from cutting edge biopharma and world-leading academic vectorology groups are invited to share clinically meaningful insights on how to enhance existing vectors and pioneer radical novel approaches to deliver genes more efficiently and safely.
In her segment, “Investigating the Promise of Redosing in Gene Therapy with EVADER™” CEO Genine Winslow will speak on Chameleon Biosciences’ innovative EVADER (patent pending) platform which we hope will specialize in giving people with genetic diseases who were previously untreatable the chance to live normal lives. In her presentation, Genine will discuss novel dosing regimens as well as the underlying biology of the human immune response that Chameleon’s EVADER is able to bypass.
For more information on the Next Generation Gene Therapy Vectors Summit and Genine’s presentation, visit https://finance.yahoo.com/news/chameleon-biosciences-founder-speak-gene-120000859.html.